FMP
Cogent Biosciences, Inc.
COGT
NASDAQ
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
6.71 USD
0.1 (1.49%)
About
ceo
Mr. Andrew R. Robbins M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.cogentbio.com
exchange
NASDAQ
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 a...
CIK
0001622229
ISIN
US19240Q2012
CUSIP
19240Q201
Address
200 Cambridge Park Drive
Phone
617 945 5576
Country
US
Employee
164
IPO Date
Mar 29, 2018
Summary
CIK
0001622229
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
19240Q201
ISIN
US19240Q2012
Country
US
Price
6.71
Beta
-0.08
Volume Avg.
2.13M
Market Cap
697.26M
Shares
-
52-Week
3.67-13.5
DCF
0.43
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.77
P/B
-
Website
https://www.cogentbio.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest COGT News
It looks like there's no news available.
